Search form

Boston Scientific Corporation has acquired EndoTex Interventional Systems. The acquisition follows the FDA approval of the NexStent Carotid Stent System, which was studied in the CABERNET trial along with the Boston Scientific FilterWire EZ Embolic Protection System. Terms of the acquisition were not disclosed. "Combining the resources of these two organizations demonstrates Boston Scientific's commitment to leadership in treating carotid artery disease," said John Pedersen, president of Boston Scientific's Peripheral Interventions business. "Incorporating the NexStent Carotid Stent into our portfolio of available carotid artery products allows us to offer physicians expanded treatment options." EndoTex is a privately held, development stage medical device company focused on a less-invasive solution to treating carotid artery disease. The company develops interventional vascular therapeutic systems designed to reduce the need for re-intervention, thereby providing improved quality of life, while reducing the cost of patient care.

Imaging Sciences International has been acquired by Danaher Corporation. Hatfield, Pa.-based Imaging Sciences manufactures, sells and markets the i-CAT Cone Beam 3D dental imaging system, a 3D imaging system for general practitioners and dental specialists. The technology is able to capture views of critical anatomy, including bone structure and tooth orientation, enables dental professionals to improve patient care by more accurately planning procedures such as implants and oral surgery. According to the company, these advantages have driven adoption of Cone Beam 3D dental imaging solutions, as has the steady growth in general dentistry, implant procedures, oral surgery, temporomandibular joint analysis, and periodontal and orthodontic procedures. In North America, i-CAT is exclusively distributed through Sullivan Schein Dental. i-CAT is distributed outside the United States by several other distributor partners.

Omtool, a provider of document handling technologies has purchased Danvers, Mass.-based BlueChip Technologies. The deal is valued at approximately $4.1 million. BlueChip Technologies specializes in document-centric technologies for the healthcare market. The company brings a customer base of more than 100 healthcare providers and will put to use in order to augment Omtool’s experience in the healthcare vertical market. It is expected portions of the BlueChip Technologies product line will be leveraged in additional verticals beyond healthcare such as legal and financial services. BlueChip Technologies will become part of Omtool. Omtool will market the BlueChip Technologies solutions as standalone products while integrating them into its larger AccuRoute product line.